

The Project

Cardiovascular disease remains the leading killer of adults globally. Whilst inflammation is known to play a key role in an individual's pathophysiological response to modifiable risk factors, pharmacotherapeutic attempts to target this have been limited. Our multi-disciplinary team, with expertise spanning from medicinal chemistry to preclinical models of disease and clinical translation, have developed a new class of "anti-inflammatory" compounds that is showing promise for a broad range of common cardiovascular disease states.

In this program of work, an aspiring researcher with a passion for drug discovery and translation, will be supervised and mentored by three complementary scientists: a leading medicinal chemist, a clinical academic interventional cardiologist, and an industry leader. The candidate will work on novel compounds which will be tested for efficacy against patient-derived monocytes from acute coronary syndrome patients, stable coronary artery disease patients and healthy controls, as well as conduct preclinical testing of these compounds on models of atherosclerosis and heart failure.

This is a dedicated project funded by NSW Health and will be conducted within the Cardiothoracic and Vascular Health Team at the Kolling Institute of Medical Research, RNSH, with primary supervision by Professor Gemma Figtree.

For further information please contact:

Professor Gemma Figtree

gemma.figtree@sydney.edu.au

Figtree Team Administration

figtree-group.admin@sydney.edu.au